Home/Learn/Does Ozempic cause muscle loss?

GLP-1 & muscle

Does Ozempic cause muscle loss? What the research actually shows

A meaningful share of the weight you lose on a GLP-1 is lean mass, not fat. Here is what the trial data shows, why it happens, and the two things proven to protect your muscle.

Key takeaways

  • Reviews of GLP-1 trials place lean mass at roughly 15 to 40 percent of total weight lost.1
  • In the SURMOUNT-1 DXA substudy, about 26 percent of the weight lost on tirzepatide (Mounjaro, Zepbound) was lean tissue.2
  • Losing lean mass does not always mean losing strength in the short term, but muscle is your reserve for the day you stop.
  • Resistance training during weight loss offset about 93.5 percent of diet-induced lean-mass loss in a meta-analysis.3
  • Protein near 1.6 g/kg per day is where added protein stops improving training gains in pooled data.4

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce weight loss that used to require surgery. That is exactly why the composition of the weight matters. The number on the scale does not distinguish fat from muscle, and a portion of what disappears is lean tissue: the skeletal muscle that keeps you strong, mobile, and metabolically healthy.

This is not a reason to avoid the medication. It is a reason to train and eat in a way that steers the loss toward fat. Below is what the published evidence says, stated plainly, including where it runs out.

How much of GLP-1 weight loss is muscle?

Across the GLP-1 trials that measured body composition, reviews place lean mass at roughly 15 to 40 percent of total weight lost.1 The single most useful data point comes from the SURMOUNT-1 DXA substudy, which used dual-energy X-ray absorptiometry to separate fat from lean tissue in people taking tirzepatide. About 74 percent of the weight lost was fat and about 26 percent was lean mass.2

For context, the headline trials produced large losses: semaglutide 2.4 mg drove about 14.9 percent mean weight loss over 68 weeks in STEP 1,5 and tirzepatide reached about 20.9 percent at its highest dose in SURMOUNT-1.6 A quarter of a loss that large is a substantial amount of muscle. One routine-care preprint, which has not yet been peer reviewed, reported a greater lean-mass decline on tirzepatide than on semaglutide outside of trial conditions.7

Why it happens

Three things line up against your muscle at once. First, rapid weight loss of any kind pulls from lean tissue as well as fat; this is true of dieting, surgery, and medication alike. Second, GLP-1 drugs suppress appetite hard, and protein is usually the first thing to fall when you are barely hungry. Third, low energy and nausea during dose escalation make it easy to stop training in exactly the window when training matters most.

The result is a diet that is high in deficit and low in the two inputs, protein and mechanical load, that tell the body to keep muscle.

Does losing lean mass mean losing strength?

Not necessarily, and this is where honest sources and alarmist ones part ways. Several short-to-mid-term GLP-1 trials found that grip strength held steady even as lean mass fell. But "lean mass" on a DXA scan includes water and organ tissue, not just contractile muscle, so a drop on the scan is an imperfect proxy for how strong you are. Longer-term research in older adults tells a more cautious story, with reports of reduced strength and function.8

The practical reading: do not panic over a lean-mass number in isolation, and do not assume you are fine just because you feel the same at month three. Track what you can actually load in a few basic movements over time. Strength is the outcome that matters, and it is the one you can defend.

What actually protects your muscle

Two levers have strong evidence behind them, and they are the same two the appetite and side effects work against.

Resistance training. In a meta-analysis of older adults losing weight through caloric restriction, adding resistance training offset about 93.5 percent of the lean-mass loss, a difference of roughly 0.82 kg of preserved lean tissue versus dieting alone.3 You do not need to be an athlete or even own equipment; you need to load your major muscle groups a few times a week and progress over time.

Protein. A dose-response meta-analysis of 49 studies found that protein supplementation improved resistance-training gains up to a breakpoint of about 1.6 grams per kilogram of body weight per day, beyond which more protein added little.4 During active weight loss, most lean-mass research supports aiming for the 1.6 to 2.2 g/kg range. That is roughly double the standard 0.8 g/kg dietary reference intake, and hitting it on a suppressed appetite takes a deliberate plan.

Go deeper

The complete, fully-cited protocol

Our 30-page handbook turns the evidence on this page into an exact plan: two training routines plus a bodyweight-only option, a protein strategy built for a suppressed appetite, training through side effects, and the maintenance phase. Every claim is cited to the research.

See the handbook — $5 →

What the evidence does not say

Two honest limits are worth stating, because most articles gloss over them. The STEP trials did not track fat-versus-muscle composition during the weight-regain phase, so the common claim that regained weight is "all fat" is not supported by those trials. And no long-term trial has isolated the effect of a structured resistance-training program specifically in GLP-1 users; the training evidence is strong but extrapolated from broader weight-loss populations. Dedicated trials such as LEAN-PREP are now underway.9

The bottom line

Yes, part of GLP-1 weight loss is muscle, on the order of a quarter of it in the best-measured trial. That is not an argument against the medication; it is an argument for training and protein while you take it. The weight you lose should be the weight you meant to lose, and the muscle you keep is what protects your results if you ever come off. About two-thirds of lost weight returned within a year of stopping semaglutide in the STEP 1 extension,10 which is exactly why the muscle you defend now is worth the effort.

Frequently asked

Does Ozempic cause muscle loss?

Yes, part of the weight lost on GLP-1 medications is lean mass rather than fat. Reviews of the trial data place lean mass at roughly 15 to 40 percent of total weight lost, and the SURMOUNT-1 DXA substudy measured about 26 percent of tirzepatide weight loss as lean tissue. Resistance training and adequate protein are the evidence-based countermeasures.

Is losing muscle on Ozempic dangerous?

Some lean-mass loss is expected with any large weight loss, and short-term trials often show preserved grip strength. The concern is longer term: muscle is harder to rebuild than fat, and it is the reserve you rely on if you regain weight after stopping. About two-thirds of lost weight returned within a year of stopping semaglutide in the STEP 1 trial extension.

How do I stop losing muscle on a GLP-1?

Two levers are supported by strong evidence: resistance training and enough protein. In a meta-analysis of older adults, resistance training during caloric restriction offset about 93.5 percent of diet-induced lean-mass loss. Protein intake around 1.6 grams per kilogram of body weight per day is the point beyond which added protein stops improving training gains in the pooled data.

References

  1. Neeland IJ, et al. Changes in lean body mass with established and emerging GLP-1-based therapies and mitigation strategies. Diabetes, Obesity & Metabolism. 2024. doi.org/10.1111/dom.15728
  2. Look M, et al. Body composition changes during weight reduction with tirzepatide (SURMOUNT-1 DXA substudy). Diabetes, Obesity & Metabolism. 2025. pmc.ncbi.nlm.nih.gov/articles/PMC11965027
  3. Sardeli AV, et al. Resistance training prevents muscle loss induced by caloric restriction in obese elderly: a systematic review and meta-analysis. Nutrients. 2018;10(4):423. mdpi.com/2072-6643/10/4/423
  4. Morton RW, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance-training-induced gains. British Journal of Sports Medicine. 2018. pmc.ncbi.nlm.nih.gov/articles/PMC5867436
  5. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021. pubmed.ncbi.nlm.nih.gov/33567185
  6. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022. pubmed.ncbi.nlm.nih.gov/35658024
  7. Murugadoss K, et al. Greater lean-body-mass decline with tirzepatide than semaglutide in routine care (preprint, not peer-reviewed). medRxiv. 2026. medrxiv.org
  8. Prokopidis K. GLP-1 receptor agonists and muscle strength changes in older adults: risks beyond muscle mass reductions. British Journal of Pharmacology. 2026. pubmed.ncbi.nlm.nih.gov/41577337
  9. LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide (LEAN-PREP). ClinicalTrials.gov NCT06885736. clinicaltrials.gov/study/NCT06885736
  10. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity & Metabolism. 2022. pmc.ncbi.nlm.nih.gov/articles/PMC9542252